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Albuminuria, not only a cardiovascular/renal risk marker, but
also a target for treatment? Albuminuria has been identified
as a marker for predicting both cardiovascular and renal risk.
From normal to overt proteinuria levels, albuminuria shows a
continuous marked increase in risk. This is independent of other
well-known cardiovascular and renal risk markers and factors,
such as blood pressure, cholesterol, smoking, overweight, and
others. The predictive power is not only present in already dis-
eased populations with either nondiabetic or diabetic renal dis-
ease, but also in hypertensive and even in otherwise healthy
populations.
New antihypertensive intervention strategies, such as
angiotensin-converting enzyme (ACE) inhibitors and an-
giotensin II (Ang II) receptor-antagonists are claimed to
have cardioprotective and renoprotective benefits that go be-
yond blood pressure control. Interestingly, these new thera-
peutic classes share the ability to lower urinary albumin ex-
cretion by an average of 40%, a characteristic that is not
observed with the other antihypertensive drug classes. This
short-term–induced antiproteinuric effect appears to predict
the long-term cardiovascular and renal protection: the more
albuminuria is lowered, the more that individual (or group) is
protected.
These data suggest that albumin is not only a risk marker
for cardiovascular and or renal disease, but it may also be a
useful target for therapy. Monitoring of albuminuria should be
daily practice in subjects at risk for cardiovascular and renal dis-
ease. In addition to new clinical trials that prove that albumin
can be targeted to obtain cardiovascular protection, guidelines
should be made to help the physician in deciding how to mea-
sure albumin in the urine, what are normal levels, how to target
“abnormal” levels, and how low we should go.
The fact that proteinuria can be used as a predictor for
renal outcome has been known for many years. Williams
and Bone showed an elegant correlation between a given
level of proteinuria and the renal outcome [1]. Remuzzi
and Bertani [2] summarized the evidence for a pathophys-
iologic link between proteinuria and progressive renal
function loss. In patients with diabetes it has been clearly
demonstrated that albuminuria is a bad sign, heralding
an increased chance for diabetic nephropathy. Recently,
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more and more data show that the link is not restricted to
the diabetic kidney, but that albuminuria also is involved
in marking the risk for cardiovascular and kidney disease
in the general population. This short overview summa-
rizes the currently available data that have evaluated the
role of urinary albumin or protein as a marker of renal
and cardiovascular risk. In addition, it tries to identify
the role that reducing albuminuria can play in therapy
guidance.
Overt albuminuria or proteinuria as risk marker
for cardiovascular and renal disease
Several studies have demonstrated that high levels
of urinary albumin (for practical purposes defined as
>300 mg/day) are associated with both an increased risk
of progressive renal function loss, as well as cardiovascu-
lar (CV) risk [1–7].
As far as the general population is concerned, initial
data from the Framingham group showed that the mere
presence of proteinuria determines the cardiovascular
outcome [6]. Iseki et al [3] showed in a 16-year follow-up
of the general population that dipstick positive for urinary
albumin gives a considerable higher chance of end-stage
renal disease (ESRD) at later life. Similar data were ob-
tained in a group of hypertensive individuals. Samuelsson
et al [7] showed that there is an increased cardiovascu-
lar risk in those with proteinuria versus nonproteinurics,
even if one treats the blood pressure. Effects of protein-
uria on the kidney in hypertensive subjects have also been
claimed [8]. In advanced diabetes, it was recently shown
in post-hoc analyses of the RENAAL and other stud-
ies that proteinuria not only determines renal outcome
[9, 10], but also cardiovascular outcome [11, 12]. Similar
data were obtained in the IDNT study [13].
Normal albuminuria or microalbuminuria as risk marker
for CV and renal disease
The definition of normal albuminuria was set years
ago, suggesting that levels above 30 mg/day (or in
concentrations >20 mg/L) are abnormal. Levels be-
tween 30 and 300 mg/day are called microalbuminuria,
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suggesting that this is a modestly elevated level of urinary
albumin. Interestingly, we learned from the diabetolo-
gists that slightly increased levels of albumin form a great
risk for the diabetic patient to develop nephropathy [14,
15].
In the general population, Hillege et al have previously
shown in the PREVEND study that at each higher level of
albuminuria from normal to overt proteinuria cardiovas-
cular risk is predicted to increase in a continuous fashion
[16, 17]. These data were corroborated by the HUNT and
EPIC studies [18, 19]. The predictive power of microal-
buminuria on cardiovascular risk is present irrespective
of other risk markers. New and presented in this supple-
ment are the data from Asselbergs et al, who show that
microalbuminuria might indeed add to the overall Fram-
ingham score as an additional tool to optimize therapy
[20]. For renal risk to be assessed in the general popu-
lation, time to event takes obviously too long for many
studies. The above mentioned Japanese study by Iseki
et al is, however, long enough, and indeed shows that a
single “+” dipstick is already associated with increased
ESRD [3]. Verhave et al show in this supplement in the
PREVEND study, that high normal levels of albumin, as
well as microalbuminuria, are associated with renal risk
[21]. Also, in the hypertensive population, at low levels of
albuminuria (even in the normal range), patients with hy-
pertension in both the LIFE and the AASK trials showed
an increased cardiovascular risk with each increase in al-
bumin levels [22, 23]. In patients with several cardiovas-
cular risk factors present, albuminuria is also a predicting
outcome, as shown by the data from the HOPE trial [24].
In diabetes, it has been long known that microalbumin-
uria is a predictor of renal as well as cardiovascular risk
[14, 15, 25, 26].
Mechanism of albuminuria linking it to CV and renal risk
Why is albuminuria an independent risk marker for
both cardiovascular as well as renal disease? The most
likely current explanation is that urinary albumin leak-
age, in fact, reflects a generalized vascular dysfunction, in
particular endothelial dysfunction. Endothelial dysfunc-
tion may be the cause for accelerated atherosclerosis, and
thus, CV and renal risk. Alternatively, albumin leakage
itself may cause vascular inflammation, thus, further dam-
aging the microvessels. Indeed, there is a lot of evidence
that microalbuminuria is associated with endothelial dys-
function [27], but much work needs to be done to really
prove how this link plays a pathophysiologic role in CV
disease [28]. Although the above mechanism may be in
play with the kidney, as well, a lot still has to be explained.
The fact that microalbuminuria would reflect endothe-
lial dysfunction is hard to explain in the kidney, given
the different vascular architecture of the glomerular vas-
culature. However, the subsequent pathway that leaked
albumin, after (proximal) tubular uptake, brings an in-
flammatory circle into play, and could be similar to the
mechanism of damage in other tissues [29].
Albuminuria reduction as measure of CV and
renal protection
The important question whether albuminuria should
be an individual target for therapy can clearly not be
answered by overwhelming pathophysiologic evidence.
However, another way of proving that albuminuria
should be targeted is bringing forward evidence that al-
buminuria lowering by itself proves to be CV and renal
protective.
Several measures are at our disposal to lower albumin-
uria, such as dietary protein restriction [30], nonsteroidal
anti-inflammatory drugs [31], angiotensin-converting en-
zyme (ACE) inhibitors [32], and angiotensin II (Ang II)
receptor antagonists [33]. The latter two options are par-
ticularly effective in cases of dietary sodium restriction
and/or addition of diuretics [34, 35]. Interestingly, all of
these measures are by themselves renal protective, and
for those properly studied, also CV protective [5, 36–40].
To start proving that this renal/CV protection is actually
related to the antiproteinuric or antialbuminuric effect,
one should at least establish that those who do not show
a decrease in albuminuria upon start of treatment do not
show renal/CV protection, whereas protection was af-
forded in those where the intervention induced an albu-
minuria reduction.
In patients with high levels of albuminuria or protein-
uria, Apperloo et al, as well as Rossing et al, showed that
the degree of albuminuria/proteinuria reduction is asso-
ciated with a more beneficial renal outcome in the long
run [41, 42]. These data showed that the degree of early
reduction in high levels of urinary albumin is associated
with the long-term renal prognosis of the individual pa-
tient. This is similar to what one has demonstrated with
other risk factors, such as hypertension or hypercholes-
terolemia, in which cases short-term reduction of the risk
markers (or in this case factors) is associated with CV
risk reduction. Meta-analysis of some of the larger renal
protection trials with ACE inhibitors showed that reduc-
tion in albuminuria is indeed associated with renal protec-
tion in nondiabetic renal disease [4]. Recently, we showed
that in diabetes a similar phenomenon is true. The more
one reduces albuminuria in patients with type 2 diabetes
with nephropathy the more these patients were protected
against development of ESRD [10]. This was irrespective
of changes in all other risk markers/factors. In fact, the en-
hanced protective effect of the Ang II receptor antagonist
losartan (compared to conventional antihypertensives)
was nearly fully explained by its antiproteinuric ef-
fect. Similar data were obtained in the IDNT trial with
irbesartan, although the authors raise a caveat with
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respect to the interpretation of such data [13]. Recently,
the first data were gathered showing that this antialbu-
minuric response is not only predicting the renal but also
the CV protection in these diabetic patients [11].
Not only in advanced (non)-diabetic renal disease, one
may find that lowering of albuminuria is predictive of
CV/renal protection. Also, in incipient diabetes with hy-
pertension, Parving et al showed in the IRMA-2 trial that
lowering of albuminuria with Ang II receptor antagonist
irbesartan is associated with less progression to diabetic
nephropathy [43].
Recently, trials in hypertensive subjects like the LIFE
and AASK have evaluated and found some interesting
data on the question of whether CV or renal risk reduc-
tion is associated with albuminuria reduction. Needless to
say, more trials are needed, specifically those that target
albuminuria reduction and analyze whether it is associ-
ated with CV/renal protection. The fact that the effect of
drugs such as ACE inhibitors as well as Ang II antagonists
can be titrated to their antiproteinuric/antialbuminuric
effect irrespective of their effect on blood pressure is im-
portant for the design of such a trial, as well as later for
clinical practice [44, 45]. Recently, Asselbergs et al have
indeed shown that ACE inhibitors offer CV protection
in subjects that have no other risk factor than increased
amount of albumin in the urine [46]. This may well be
the lead to a new era, in which albuminuria is by itself a
target for treatment.
How, when, and where to measure?
Standard techniques for measuring albumin in urine
are nearly all based on antibody interaction with albu-
min. There are several ways of detecting this complex,
varying from radiolabels and coloring of the complex,
to precipitation techniques, such as nephelometry. All
these techniques have in common that they detect im-
munoreactive albumin (in urine or serum). Recently, it
was found that albumin also appears in urine in a non-
immunoreactive form. This can be measured by a novel
high-performance liquid chromatography (HPLC) tech-
nique (AccuminTM; AusAm Biotechnologies, Inc.). Sev-
eral authors have found that this new technique may pick
up microalbuminuria in earlier stages of the disease, and
may be even more sensitive in its relation with CV disease
[47–49].
All these techniques have in common that they need to
be carried out in a standardized laboratory environment.
Although albuminuria can be semiquantitatively mea-
sured with a urine dipstick technique (MicralTM; Roche
Laboratories), accurate measurements in the field may
be extremely valuable both in a setting of the future
practicing physician needing to titrate his medication to
albuminuria, but also in the current setting for devel-
oping countries. Fortunately, new devices are available
that can accurately and rapidly measure albumin with
“desktop” machines (Hemocue Urine AlbuminTM, Bayer
DCA 2000).
When should we test urine for albumin? Certainly in
the case of diabetes, urine albumin testing is obligatory
according to the guidelines. In the case of hypertension,
it is certainly advisable (and according to some guide-
lines, more than recommendable) that one measures uri-
nary albumin because it enhances the risk profiling of
the individual. In the future, it may become standard to
test the general population visiting the general physician
for the presence of albumin in the urine. However, such
a standard use will clearly depend on the outcome of
urgently needed prospective, randomized intervention
trials targeting albuminuria for cardiovascular protec-
tion. An exception may be the use of such urine albu-
min measurements in the developing countries. As one
may appreciate from the work of Correa-Rotter et al [50]
derived from the recent ISN-COMGAN Bellagio meet-
ing [51], the need for simple and inexpensive predictors
for CV/renal morbidity and mortality is rising dramat-
ically in developing countries. Next to blood pressure,
albuminuria and renal function by serum creatinine may
be such “easy” markers for risk. In these countries, this
may well lead to early (primary) intervention strategies,
certainly given the fact that treatment in advanced [52],
as well as early stages of albuminuria appears to be cost-
effective [53].
Finally, having a measurement of albumin in the urine
should lead to action in case the result is “abnormal.” The
definition of normal is now still based on the historic find-
ings in diabetes, in which microalbuminuria is defined as
“abnormal,” ranging from 30 to 300 mg of albumin in the
urine per day. Because daily collection of urine is very
cumbersome, spot urine collections are often preferred.
This leaves only concentration of albumin in the urine as a
measure, giving normal ranges between 20 and 200 mg/L.
Because urine may be diluted or concentrated, correction
of albumin concentration values using urinary creatinine
is often practiced. However, gender differences in urinary
creatinine excretion may further complicate this issue.
Until proven differently, the standard for normal urinary
albumin levels should thus be <30 mg/day or <20 mg/L.
This allows correct interpretation of all of the data from
the past. Changing borders will only lead to more con-
fusion. Certainly, just like with the definition of normal
blood pressure, boundaries for normal albuminuria will
shift in the future [17, 22, 54, 55].
CONCLUSION
Urinary albumin excretion is a powerful independent
marker for both CV and renal risk in healthy subjects,
as well as in patients with different comorbid condi-
tions. Albuminuria may reflect a generalized vascular
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dysfunction. Treatment regimens that lower albuminuria
are associated with both CV and renal protection. The
more albuminuria is lowered, the better the patient is
protected. Future trials may provide us with the data that
ensures that albuminuria should be measured in all sub-
jects, and that, in case of abnormal high levels, treatment
should be initiated that lowers the albuminuria as much
as possible. Albuminuria may thus become a modifiable
CV/renal risk factor just like high blood pressure and/or
cholesterol.
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